

Beneficiary Information

1. Beneficiary Last Name: _____	2. First Name: _____
3. Beneficiary ID #: _____	4. Beneficiary Date of Birth: _____
5. Beneficiary Gender: _____	

Prescriber Information

6. Prescriber Name: _____	NPI #: _____
Mailing address: _____	City: _____ State: _____ ZIP: _____
7. Requester Contact Information: _____	
Name: _____	Phone #: _____ Fax #: _____

Drug Information

8. Drug Name: _____	9. Strength: _____	10. Quantity per 30 days: _____
11. Length of Therapy: ___up to 30 days ___60 days ___90 days ___120 days ___180 days ___365 days ___Other: _____		

Clinical Information ***Submit medical records to support all responses below.***

For initial requests (Wegovy, Saxenda, and Zepbound):

1. Please list the beneficiary's baseline weight and BMI. Weight _____ Date _____ BMI _____ Date _____
2. Is the beneficiary 18 years or age or older? Yes ___ No ___
 - 2a. Does the beneficiary have a BMI greater than or equal to 30 kg/m²? Yes ___ No ___
 - 2b. Does the beneficiary have a BMI greater than or equal to 27 kg/m²? Yes ___ No ___
 - 2b-i. Does the beneficiary have at least one weight-related comorbidity/risk factor/complication (i.e., hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, dyslipidemia)? Yes ___ No ___
- Please list: _____
3. Is the beneficiary between 12-17 years of age? Yes ___ No ___
 - 3a. Does the beneficiary have a BMI greater than or equal to the 95th percentile for age and sex? Yes ___ No ___
 - 3b. Does the beneficiary have a BMI greater than or equal to 30 kg/m²? Yes ___ No ___
 - 3c. Does the beneficiary have a BMI greater than or equal to the 85th percentile for age and sex? Yes ___ No ___
 - 3c-i. Does the beneficiary have at least one weight-related comorbidity/risk factor/complication (i.e., hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, dyslipidemia)? Yes ___ No ___
- Please list: _____
4. Is the beneficiary 45 years of age or older? Yes ___ No ___
 - 4a. Does the beneficiary have a BMI greater than or equal to 27 kg/m²? Yes ___ No ___
 - 4a-i. Does the beneficiary have established cardiovascular disease (CVD) defined as having a history of myocardial infarction, stroke, or symptomatic peripheral disease? Yes ___ No ___
- Please list: _____
5. Is the beneficiary currently on and will the beneficiary continue lifestyle modification including structured nutrition and physical activity, unless physical activity is not clinically appropriate at the time GLP1 therapy commences? Yes ___ No ___
6. Will the beneficiary be using the requested agent with another GLP-1? Yes ___ No ___
7. Does the beneficiary have any FDA-labeled contraindications to the requested agent, including pregnancy, lactation, history of medullary thyroid cancer or multiple endocrine neoplasia type II? Yes ___ No ___

Continuation Requests (Wegovy, Saxenda, and Zepbound):

8. Has the beneficiary previously been approved for the requested agent through NC Medicaid's PA process? Yes ___ No ___
9. Beneficiary's baseline and current weight. Baseline Weight _____ Date _____ Current Weight _____ Date _____
10. Beneficiary's baseline and current BMI. Baseline BMI _____ Date _____ Current BMI _____ Date _____
11. Is the beneficiary continuing a current weight loss course of therapy? Yes ___ No ___
12. **Ages 18 and older** – Has the beneficiary lost a total of 5% of pretreatment weight and is maintaining the 5% weight loss? Yes ___ No ___
Baseline Weight _____ Current Weight _____
13. **Ages ≥ 12 to <18 years** – Has the beneficiary had >4% reduction in baseline BMI and is maintaining the weight loss? Yes ___ No ___
Baseline Weight _____ Current Weight _____
14. Does the beneficiary have a documented weight loss that is deemed to be a significant reduction from BMI per the prescriber and the weight loss is maintained, yet the 5% (for adults) and 4% (for adolescents) is not met? Yes ___ No ___

Rationale: _____

Fax this form to: 1-877-234-4274, or call Pharmacy Prior Authorization: 1-866-885-1406

North Carolina

15. Is the beneficiary currently on and will continue lifestyle modification including structured nutrition and physical activity?

Yes ___ No ___

16. Will the beneficiary be using the requested agent with another GLP-1? Yes ___ No ___

17. Does the beneficiary have any FDA-labeled contraindications to the requested agent, including pregnancy, lactation, history of medullary thyroid cancer or multiple endocrine neoplasia type II? Yes ___ No ___

Requests for Non-Preferred Drugs (Saxenda, and Zepbound):

1. ___ Failed preferred drugs. List preferred drugs failed: _____

1a. ___ Allergic Reaction 1b. ___ Drug-to-drug Interaction Please describe reaction: _____

2. ___ Previous episode of unacceptable side effect or therapeutic failure. Please provide clinical information: _____

3. ___ Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s).

Please provide clinical information: _____

4. ___ Age specific indications. Please give patient age and explain: _____

5. ___ Unique clinical indication supported by FDA approval or peer reviewed literature.

Please explain and provide a general reference: _____

6. ___ Unacceptable clinical risk associated with therapeutic change. Please explain: _____

Signature of Prescriber: _____

Date: _____

***Prescriber signature mandatory**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.